FDA approves olaparib with abiraterone for metastatic prostate cancer

Olaparib (Lynparza) with abiraterone (Zytiga)—plus prednisone (or prednisolone)—is indicated for adults with BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved diagnostic test. Efficacy was evaluated in the phase 3 PROpel trial (N=796), which showed improved radiological progression-free survival with olaparib-abiraterone vs. placebo-abiraterone.